CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –Kytopen Corp., an MIT-spun biotech company offering scalable technology for modified cell therapies, today announced it has raised $ 30 million in oversubscribed Series A funding. The new capital will be used to commercialize Kytopen’s Flowfect® Tx for the manufacture of GMP-compliant cell therapies and to progress towards treating the first human patient with modified Flowfect® cells. Kytopen’s mission is to enable simple and effective non-viral manufacture of cell therapies in days instead of weeks to increase patient access to life-saving therapies.
The Series A investor syndicate was led by the experienced life sciences investment team of Northpond Ventures, a leading science-based venture capital firm, with the participation of current investors: Engine, Horizon Ventures, and Mass enterprises, as well as Aldevron co-founders Michael Chambers and John Ballantyne and Alexandria Venture Investments. Adam Wieschhaus, Ph.D., CFA, Principal at Northpond Ventures, will join the Kytopen Board of Directors alongside Kytopen Co-Founders Paulo Garcia and Cullen Buie and Theresa Tribble, Venture Partner at The Engine.
“We are delighted to partner with Northpond and their innovative ecosystem to develop and commercialize our Flowfect technology. Together with the talented and experienced team at Northpond, we will continue to unlock industry bottlenecks and pave the way for cost-effective engineered cell therapies, ”said Paulo Garcia, Ph.D., CEO and co-founder of Kytopen. “We are actively leading therapeutic and academic collaborations and this funding and network will be the catalyst to accelerate our partners in the clinic and beyond. I am extremely proud of the achievements and future contributions of the entire Kytopen team in making these potentially life-saving cell therapies more accessible to patients.
The new funding will also accelerate the commercialization of Kytopen’s high-throughput automated platform, which seamlessly links discovery to manufacturing and has the potential to unlock personalized drugs. The company’s proprietary Flowfect® platform is a transformative solution that eliminates the complexity of gene editing and integrates discovery, development and manufacturing into a flexible and scalable non-viral delivery solution.
“Cellular engineering is a very manual and time consuming process. While the market demands acceleration and scale, the fragility of a cell demands that the methods be equally gentle from the lab to the clinic, ”said Adam Wieschhaus, Ph.D., CFA, director at Northpond Ventures. “Kytopen unleashes the potential of genetic engineering at speeds 10,000 faster than current advanced methods while maintaining cell composition. Northpond is excited to work with Kytopen to advance non-viral manufacturing and bring much-needed cell therapies to patients. ”
Kytopen’s proprietary Flowfect® technology accelerates discovery-to-clinic therapies by enabling cell engineering without compromising functionality or viability. Flowfect® reduces risk and provides maximum control and flexibility to reduce time-to-market by months or even years, while providing safer and more cost-effective cell therapies.
Flowfect® technology uses electromechanical energy to gently introduce genetic material such as RNA, DNA or CRISPR / Cas RNP, into a wide variety of difficult-to-transfect primary human cells. Flowfect® technology enables cell engineering in minutes for target discovery and process development optimization. For example, 96-well plates can be processed in less than 10 minutes while scaling directly to clinical manufacturing volumes is facilitated by the processing rate of 2 billion cells per minute in a single channel .
About Northpond Ventures
Northpond Ventures is a science-based venture capital firm. Northpond partners with leading scientists, academics and entrepreneurs to develop and strengthen the cutting-edge science and technology that is transforming humanity. The company has more than $ 2 billion in committed capital and offices in San Francisco, Cambridge and Bethesda. Northpond was founded with a mission to build a better tomorrow. Northpond Labs, the company’s research and development-focused subsidiary, works with universities, research centers and scientists to fund translational research that is fast becoming the foundation for new ventures and scientific discovery. Learn more about www.npv.vc.
Kytopen, a spin-out of Professor Cullen Buie’s lab at MIT, is a transformative biotech company that delivers a customizable yet scalable multi-solution platform that seamlessly connects the discovery, development, and manufacturing phases of cell engineering. Flowfect®, a gentle, non-viral delivery method, paves the way for new therapeutic approaches, creating immune cells with minimal disruption, preserving human cell functionality and viability, and improving cell biology. The Flowfect® platform accelerates bench-to-clinical therapies through flexibility and scalability, resulting in higher cell yields, faster approvals, and better outcomes of potentially curative cell treatments. For more information visit: www.kytopen.com